NewAmsterdam Pharma Company N.V. (NAMS) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
NAMS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NAMS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 99.7% | -1002.9% | -905.7% |
| 2024 | 100.0% | -386.9% | -530.3% |
| 2023 | 100.0% | -1298.6% | -1255.8% |
| 2022 | 100.0% | -3.5% | -22.0% |
| 2021 | - | - | - |
Download Data
Export NAMS earnings history in CSV or JSON format
Free sign-in required to download data
NewAmsterdam Pharma Company N.V. (NAMS) Earnings Overview
As of May 17, 2026, NewAmsterdam Pharma Company N.V. (NAMS) reported trailing twelve-month net income of -$213M, reflecting +31.6% year-over-year growth. The company earned $-1.76 per diluted share over the past four quarters, with a net profit margin of -905.7%.
Looking at the long-term picture, NAMS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2020.
NewAmsterdam Pharma Company N.V. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ESPR (-$7M net income, -5.6% margin), MDGL (-$309M net income, -30.1% margin), LNTH ($279M net income, 15.2% margin), NAMS has room to improve margins relative to the peer group. Compare NAMS vs ESPR →
NAMS Earnings vs Peers
Earnings metrics vs comparable public companies
NAMS Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$204M | +15.6% | -$226M | $-1.75 | -905.7% | -1002.9% |
| 2024 | -$242M | -36.5% | -$176M | $-2.56 | -530.3% | -386.9% |
| 2023 | -$177M | -681.7% | -$183M | $-2.15 | -1255.8% | -1298.6% |
| 2022 | -$23M | +45.8% | -$4M | $-1.19 | -22.0% | -3.5% |
| 2021 | -$42M | -495.0% | -$35M | $-3.34 | - | - |
| 2020 | -$7M | - | -$7M | $-1.15 | - | - |
See NAMS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAMS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAMS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNAMS — Frequently Asked Questions
Quick answers to the most common questions about buying NAMS stock.
Is NAMS growing earnings?
NAMS EPS is $-1.76, with earnings growth accelerating to +31.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-213M.
What are NAMS's profit margins?
NewAmsterdam Pharma Company N.V. net margin is -905.7%, with operating margin at -1002.9%. Below-average margins reflect competitive or cost pressures.
How consistent are NAMS's earnings?
NAMS earnings data spans 2020-2025. The accelerating earnings trend is +31.6% YoY. Historical data enables comparison across business cycles.